BioWorld

Jan. 29, 2007

Aranesp Data Eclipse Amgen's Fourth-Quarter Revenue Growth

Despite topping revenue estimates for the fourth quarter, Amgen's Inc.'s stock slipped more than $3 on news of unsettling Phase III Aranesp data. (BioWorld Today) Read More

Xcellerex Series B Gets $20M For FlexFactory Drug System

Opening The Risk Debate Crucial For Biotech's Future

Bush Backs Biofuel Use Yet Again In Address To Nation

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Dec. 11, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 11, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...

DEE-lightful: Praxis’ phase II results allow stock to flex its muscle

BioWorld

Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...